The healthcare industry is in the formative stages of a new era of medicine — the advent of advanced therapeutic medicinal products (ATMPs).

This paradigm shift has the potential and promise to cure debilitating disease states but equally necessitates the need to overcome key bottlenecks in the manufacturing and logistics that arise therefrom. At the forefront of ATMPs, cell and gene therapies are making headlines with curative results in patients, while newer studies are revealing the capabilities of other novel modalities like radioligand therapy, mRNA therapies, prime-/base-edited therapies (e.g., CRISPR) and conventional cell and gene therapies.

The success of ATMPs is pushing the boundaries of traditional research, manufacturing, storage and distribution. Stakeholders are demanding shorter production, development and approval timelines, in addition to a higher level of visibility and touch for these new treatments both in manufacturing and in transit. The added complexity is the ability to navigate inevitable disruptions that occur from vein-to-vein due to factors such as weather events and geopolitical events. Given the temperature-sensitivity and time-criticality the therapies are subject to, collaboration is needed to develop innovative solutions to reduce complexity and improve reliability across the entire ATMP supply chain.

Attendees will learn more about:

• Types of ATMPs currently in development, the promise of new modalities and ongoing research to diversify targeted diseases
• Evolution of regulatory framework for ATMPs as it keeps pace with rapid advancements in the field
• Approaches towards maintaining resilience and mitigating disruption for hyper-sensitive, personalized drugs in the supply chain

Register for this webinar today to understand the future of ATMPs and the strategies behind their mainstream adoption.